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Summary Chemotherapeutic management of ovarian cancers is a difficult task as these neoplasms show significant differences in
chemosensitivity, even if they share identical clinicopathological features. The present study was undertaken to investigate the prognostic and
predictive role of p53 alterations in ovarian cancer. To this end, using different technical approaches, i.e. genetic and immunohistochemical
analyses, we analysed a series of 68 ovarian neoplasms including 15 low malignant potential (LMP) tumours and 53 invasive carcinomas. We
never observed p53 abnormalities in LMP tumours. p53 alterations were present only in invasive ovarian carcinomas, and they were detected
much more frequently in tumours characterized by high histological grade (P=0.01) and advanced-stage disease (P=0.006 and P=0.05 for
gene mutations and protein expression respectively). For 33 patients with invasive ovarian cancer, information was available concerning
response to cisplatin-based chemotherapy. A strong correlation (P=O0.001) has emerged between p53 alterations and response to chemo-
therapy: only one (14%) of seven patients who had a pathological complete response to antiblastic drugs showed p53 aberrations, whereas
18 (82%) of 22 cases with partial response and all of the four non-responsive patients scored positive for p53 abnormalities. We also
observed that patients with p53 mutations had a significantly shorter progression-free survival than patients with p53-negative tumours
(P=0.05). Taken together, our results strongly suggest that in epithelial ovarian malignancies tumours showing p53 aberrations are
significantly less sensitive to chemotherapy and more aggressive than those with functional p53. Thus, a routine analysis of this gene could
have profound implications for the treatment of ovarian cancer.
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In most malignancies, drug resistance represents a major impedi-
ment to the control of neoplastic growth. Ovarian cancer presents
an example of difficult chemotherapeutic management. Despite
the improvements in therapeutic response, obtained mainly with
cis-diamminedichloroplatinum II (CDDP)-based chemotherapy,
approximately 50% of patients in advanced stage of disease are
intrinsically resistant to chemotherapy and nearly 50% of origi-
nally responsive patients develop chemoresistance during the
course of their treatment (Perez et al, 1993). In addition, ovarian
cancers may show significant differences in chemosensitivity,
even ifthey share identical clinicopathological features.
An increasing body of evidence suggests that most anti-cancer
agents commonly used in the treatment of several malignancies
may induce tumour regression by apoptosis (Hickman, 1992;
Carson and Ribeiro, 1993; Fisher, 1994; Thompson, 1995), a pecu-
liar form of cell death with biochemical and morphological
features distinct from those ofnecrosis (Majno and Joris, 1995).
The apoptotic process is modulated by some proto-oncogenes and
tumour-suppressor genes (Kerretal, 1994; Thompson, 1995). Among
the latter, thep53 gene seems to have a crucial role in the execution of
some forms of apoptosis (Yonish-Rouach et al, 1991; Shaw et al,
1992; Kerr et al, 1994). It has been shown in vitro that loss ofp53
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function, through mutations thatinterferewithapoptosis, facilitatesthe
development of neoplastic clones (Symonds et al, 1994) resistant
to different antiblastic drugs (Lowe et al, 1993a) including CDDP
(Nabeya et al, 1995). In addition,p53 mutations could exert a specific
activation of the MDR1 (multiple drug resistance) gene promoter
(Chin et al, 1992), which may result in areduced intracellular concen-
tration ofvarious chemotherapeutic agents (Juliano and Ling, 1976).
p53 alterations are common genetic events in ovarian carci-
nomas (Kohler et al, 1993; Kupryjanczyk et al, 1993; Milner et al,
1993), but at the moment it is not clear whether they have a prog-
nostic value (Bosari et al, 1993; Niwa et al, 1994; Kappes et al,
1995) and their role in chemoresistance has not been established.
The present study was undertaken to investigate the prognostic
and predictive role of p53 alterations in ovarian cancer. To this
end, we evaluated the status of the p53 gene by genetic analysis
and the expression ofthe p53 protein by immunohistochemistry in
a series of68 ovarian carcinomas. The results were compared with
well-known clinicopathological parameters of prognosis and with
response to antiblastic agents in a subset of33 patients treated with
CDDP-based chemotherapy.
MATERIALS AND METHODS
Patients and tissue samples
Sixty-eight patients with ovarian neoplasm, including 15 with
low malignant potential (LMP) tumours (Hart, 1992) and 53 with
invasive ovarian carcinoma, were analysed in this study.
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Tumour specimens were consecutively obtained at initial
surgical resection and immediately frozen at -70°C. To overcome
the limitations due to the heterogeneity ofovarian cancer, adjacent
sections oftumour were obtained in each case for DNA extraction
and for immunoperoxidase staining. In each case, segments of
normal fallopian tube or peripheral blood were collected as
controls.
The carcinomas were histologically typed and graded according
to the World Health Organization (Serov et al, 1973). Only epi-
thelial ovarian malignancies were included in this study; among
the invasive tumours there were 31 serous, ten endometrioid, three
mucinous, three clear cell and six undifferentiated carcinomas. All
LMP tumours were classified as serous. With respect to grade,
there were 12 well-differentiated (GC), 14 moderately (G2) and 27
poorly differentiated tumours (G3).
Tumour stage was determined according to the criteria of the
International Federation of Gynaecology and Obstetrics (FIGO)
(Beahrs et al, 1988). For statistical analysis, patients with stage I
and stage II disease were pooled into an early stage subgroup,
whereas patients with stage III and IV disease were pooled into an
advanced stage subgroup; 14 ofthe patients under study had stage
I-II disease and 39 patients had stage III-IV disease.
The age range ofthese patients was 41-81 years, with a median
of59 years.
Forty-six patients with follow-up data ranging from 8 to 92
months' duration were analysed for progression-free length of
survival. The evaluation ofthe clinical course ofdisease was based
on clinical examination, chest radiography, abdominal-pelvic
ultrasound and computerized tomography (CT) scan. After initial
surgery, 33 patients with stage III-IV invasive ovarian cancer
received six cycles of CDDP-based chemotherapy. The disease
progressed or remained stable in four patients. The other 29
patients who achieved a clinical complete or partial response to
chemotherapy underwent a second-look laparotomy. A patholog-
ical complete response to therapy was defined as the disappear-
ance of all tumour deposits with negative peritoneal washing and
negative multiple random biopsies.
Detection of p53 alterations by SSCP
Polymerase chain reaction-single-strand conformation polymor-
phism (PCR-SSCP) analysis (Orita et al, 1989) was performed to
detect mutations in the exon 5-8 of the p53 gene. Samples were
subjected to amplification at each exon, including the exon-intron
boundary. The technique was optimized as previously described
(Spinardi et al, 1991). Routinely, 100 ng ofgenomic DNA was used
in a 10-gl PCR reaction containing 10 mM Tris-HCl (pH8.3), 1.5
mm magnesium chloride, 50 mm potassium chloride, 0.01% (w/v)
gelatine, 1.25 mm each of four dNTPs (Boehringer Mannheim
Biochemica), 1 mm ofeach primer, 0.5 gl of[t-32P]dCTP (3000 Ci
mmol-', Amersham, Arlington, IL, USA) and 0.25 units of Taq
DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA). Four
couples of specific intronic primers, whose sequences were
deduced from Buchman et al (1988), were used:
Exon 5:
Sense: 5'-TGACTTTCAACTCTGTCTCCT
Anti: 5'-TCAGTGAGGAATGAGAGGCC
Exon 6:
Sense: 5'-CTGGAGAGACGACAGGGCTG
Anti: 5'-CCAFAFACCCCAGTTGCAAAC
Exon 7:
Sense: 5'-CTCGCGCACTGGCCTCATCTT
Anti: 5'-TCAGCGGCAAGCAGAGGCTG
Exon 8:
Sense: 5'-GGACAGGTAGGACCTGATTTCCTTAC
Anti: 5'-TGCACCCTTGGTCTCCTCCAC
Thirty amplification cycles were performed under the following
conditions: initial denaturation, 6 min at 94°C; amplification, I min
at 94°C, 1 min at 58°C, 2 min at 72°C for 30 cycles; elongation, 5
min at 72°C.
PCR products were electrophoretically separated by 6% non-
denaturing polyacrylamide gel at 10 W for 12 h at 20°C. Genomic
DNAs from tumour samples and corresponding normal ovarian
tissues were examined by separate PCR-SSCP analysis to exclude
the possibility of any polymorphism within the coding region.
Upon complete migration, the gels were dried and subjected to
autoradiography against a Kodak XAR-5 film at -80°C with an
intensifying screen. PCR was performed at least twice for each
sample, and only the reproducible cases were taken.
Immunohistochemical analysis
Immunostaining of the p53 protein was performed by the
avidin-biotin peroxidase complex method. Briefly, 4-5 ,um frozen
sections were cut, mounted on polylysine-coated slides, air dried
and fixed in cold (4°C) acetone for 10 min before being subse-
quently incubated with: (1) monoclonal antibody 1801 (Ab-2;
Oncogene Science, Vector, Burlingame, CA, USA) (diluted 1:100,
overnight at 4°C) which recognizes a denaturation-resistant epi-
tope from amino acid 32 to 79 ofthe p53 protein; (2) a biotinylated
horse anti-mouse IgG antibody (diluted 1:500, 30 min at room
temperature); (3) avidin-peroxidase complexes (1 h). Finally, the
slides were developed with 0.5% diaminobenzidine in 0.05 M Tris
buffer pH 7.4 containing 0.5% hydrogen peroxide, rinsed in tap
water, counterstained with 5% haematoxylin, dehydrated, cleared
in xylene and mounted in permanent coverslipping medium.
Positive controls were two known positive cases of human colon
cancer. Negative controls were obtained by replacement of
primary antiserum with Tris buffer.
Statistical analysis
Contingency tables were used to examine the relationship between
aberrations ofthep53 gene and each of the following clinicopatho-
logical data: stage ofdisease, residual disease, grade oftumourdiffer-
entiation, response to chemotherapy and progression-free overall
survival. Statistical association was determined by x2 analysis. A P-
value ofless than 0.05 was considered to have statistical significance.
RESULTS
p53 gene mutations
In all the LMP tumours tested, nop53 gene mutations were found.
Electrophoretic mobility shifts, indicative of mutation of p53,
were detected in 28 (53%) of 53 invasive carcinomas; 11 muta-
tions were located in exon 5, six in exon 6, eight in exon 7 and
three in exon 8 (Figure 1). A strong correlation (P=0.006) was
observed betweenp53 gene mutations and FIGO stage;p53 muta-
tions were found in 3 (21%) of 14 tumours at stage I-II and in 25
(64%) of 39 cases at stage III-IV (Table l). A higher frequency of
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Figure 1 PCR-SSCP analysis of exons 5-8 ofthe p53 gene in 14 different
cases (A-N) of ovarian carcinomas. The arrows indicate bands with mobility
shift. Common polymorphisms of the p53 gene were excluded by using DNA
from normal tissue as comparison in each patient
p53 mutations was detected in poorly differentiated tumours; of28
tumours with p53 gene alteration, two (7%) were well differenti-
ated (GI), nine (32%) moderately differentiated (G2) and 17 (61%)
poorly differentiated (G3). This difference was statistically signif-
icant (P=0.01). No correlation was present between aberrations in
thep53 gene and the histological type ofthe tumours examined. A
statistically significant association (P=O.05) was also present
between p53 gene mutations and progression-free survival; of 13
patients with short (<18 months) or absent progression-free
survival, ten (77%) hadp53 mutations.
Nuclear accumulation of the p53 protein
p53-immunoreactive cells were never observed in LMP tumours
nor in normal ovarian tissues. In all positive cases, the immuno-
reactivity was nuclear and present in more than 10% of neoplastic
cells (Figure 2). Twenty-seven (51%) of53 invasive ovarian cancers
showed a clear overexpression of the p53 protein. A correlation
_r.we.. __.i
Figure 2 Nuclear accumulation of the p53 protein in a case of poorly
differentiated ovarian carcinoma. Most of the neoplastic cells show a strong
immunostaining (immunoperoxidase technique)
(P=0.05) was foundbetween p53 nuclear accumulation and stage of
disease; 4 (15%) out of 27 cases that scored positive for p53 over-
expression were at stage I-II, whereas 23 (85%) were in advanced
stages (IH-IV). A significant association (P=0.01) was also
observed between nuclear accumulation of the p53 protein and
tumour differentiation; 2 (17%) out of 12 GI tumours, 7 (50%) of
14 G2 tumours and 18 (67%) of 27 G3 tumours were p53 positive.
This difference was statistically significant (P=0.01). p53 nuclear
accumulation was more frequently seen in patients with shorter
progression-free survival; in the group ofpatients with shorter (<18
months) progression-free survival, 69% (9 out of 13 cases) had p53
nuclear accumulation, whereas in the group of patients with longer
(>18 months) progression-free survival a p53 overexpression was
observed in 42% (14 out of 33) of cases. This difference was not
significant (P=0.1).
Table 1 p53 status and main clinicopathological features in invasive ovarian cancer
Clinicopathological Molecular analysis P-value Immunohistochemical P-value
features (SSCP) analysis
p53 p53 p53 p53
positive negative positive negative
Mean age at diagnosis (years) 58 62 NSa 58 62 NS
FIGO stage
Stage 1/ll 3 (21)b 11 (79) 4 (29) 10 (71)
Stage III/IV 25 (64) 14 (36) 0.006 23 (59) 16 (41) 0.05
Differentiation
well differentiated 2 (17) 10 (83) 2 (17) 10 (83)
moderately differentiated 9 (64) 5 (36) 0.01 7 (50) 7 (50) 0.01
Poorly differentiated 17 (63) 10 (37) 18 (67) 9 (33)
Response to chemotherapy
Complete 1 (14) 6 (86) 1 (14) 6 (86)
Partial 15 (68) 7 (32) 0.009 14 (64) 8 (36) 0.01
Absent 4 (100) 0 4 (100) 0
Progression-free survival
> 18 months 15 (45) 18 (55) 14 (42) 19 (58)
<18 months 10 (77) 3 (23) 0.05 9 (69) 4 (31) NS
aNS, not significant. bNumbers in parentheses are percentages.
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Table 2 Correlation of p53 status and chemosensitivity
Case no. Stage SSCP IHC SSCP+IHC Response to
analysisa analysisb chemotherapyc
1 III +(5) + + C
2 Il - - - C
3 Il - - - C
4 Il - - - C
5 Il - - - C
6 Il - - - C
7 Il - - - C
8 III + (5) + + P
9 III + (7) + + P
10 III + (5) + + P
11 Il + (7) + + P
12 Il +(6) + + P
13 III + (6) + + P
14 IV + (5) + + P
15 III + (7) + + P
16 IV + (5) + + P
17 III + (7) + + P
18 IV + (6) + + P
19 III + (6) - + P
20 III + (6) - + P
21 III + (5) - + P
22 III + (5) - + P
23 IV - + + P
24 III - + + P
25 III - + + P
26 III - - - P
27 III - - - P
28 III - - - P
29 IV - - - P
30 III +(6) + + NR
31 IV + (7) + + NR
32 III +(5) + + NR
33 IV + (5) + + NR
aNumbers in parentheses correspond to exon mutated. blHC,
immunohistochemistry. cC, complete; P, partial; NR, no response.
Relationship between SSCP and immunohistochemical
data
A strong correlation (P=0.001) was observed between p53 muta-
tions detected by SSCP analysis and nuclear accumulation of the
p53 protein evaluated by immunohistochemistry. The immunohis-
tochemical staining and the SSCP analysis gave concordant results
in all the LMP tumours tested. In the 53 invasive carcinomas,
corresponding results were obtained in 42 (79%) cases; p53 gene
mutation with nuclear accumulation of its protein product was
seen in 22 cases, while in 20 cases there was absence ofboth muta-
tion and overexpression. However, in 6 (21%) of 28 cases with a
p53 mutation, no nuclear accumulation was present and in 5 (20%)
of 25 cases without mutation, an immunoreactivity for the p53
protein was seen.
p53 alterations and response to chemotherapy in
invasive ovarian carcinomas
After initial cytoreductive surgery, 33 patients with advanced
(stage III-IV) invasive ovarian carcinomas were treated with six
cycles ofCDDP-based chemotherapy. p53 gene status and expres-
sion were evaluated in tumour samples obtained before therapy.
Mutations of thep53 gene were detected in 20 (61%) of 33 cases;
nine mutations were located in exon 5, six in exon 6 and five in
exon 7 (Table 2). No mutations were observed in exon 8. Using
immunohistochemistry, a nuclear accumulation ofp53 protein was
found to be present in 19 (58%) of 33 cases. A significant associa-
tion was observed between p53 alterations and response to
chemotherapy with both SSCP (P=0.009) and immunohisto-
chemical (P=0.01) methods. However, a very strong correlation
(P=0.001) emerged by cumulating the results of the genetic and
immunohistochemical analysis; p53 aberrations were observed in
only one (14%) of seven patients who achieved a pathological
complete response, in 18 (82%) of 22 patients who had partial
response and in all of the four patients who did not respond to
chemotherapy. Because of the small number of patients with
minimal residual disease (three cases), no significant relationship
was detected between residual tumour volume and p53 status or
between residual tumour volume and chemosensitivity.
DISCUSSION
Ovarian cancer is the gynaecological neoplasm with the most
aggressive behaviour and worst prognosis. In about 70% ofcases,
ovarian cancer is diagnosed in advanced stage (Piver et al, 1991);
this is presumably because of the paucity of specific, early symp-
toms and the lack of sensitive screening methods. In addition,
despite the combined use of aggressive cytoreductive surgery and
chemotherapy, long-term survival has not significantly improved
in the last few years (Bookman and Bast, 1991).
Prognosis is currently based on clinical and histopathological
factors (Friedlander and Dembo, 1991). However, the identifica-
tion of new prognostic indicators could be of great value in the
planning of individualized and potentially more effective treat-
ments. A number of genetic alterations have been observed in
ovarian cancer, but little is known about their prognostic role. C-
myc amplification (Baker et al, 1990; Sasano et al, 1992) or Ki-ras
mutations (Yaginuma et al, 1992) are involved in a very low
percentage of cases. C-erb-B2 gene amplification and/or overex-
pression has been demonstrated in 20-30% of ovarian malignant
tumours (Kacinski et al, 1992; Fajac et al, 1995), but these alter-
ations do not seem to be important in identifying subsets of
patients with poor prognosis.
So far, the gene most frequently mutated in ovarian cancer
(50-70% of cases) is p53 (Marks et al, 1991; Mazars et al, 1991;
Okamoto et al, 1991; Eccles et al, 1992). Such a high frequency of
mutations suggests an important role for this gene in ovarian
carcinogenesis. Although a consistent literature provides data indi-
cating that the loss of p53 function may have a prognostic value in
different forms of human tumours, including lung (Marchetti et al,
1993), breast (Bosari et al, 1992; Bergh et al, 1995) and prostatic
malignancies (Bauer et al., 1995), it is not clear whether p53 alter-
ations may have a similar value in ovarian cancer. In our series of
ovarian carcinomas, p53 gene aberrations were significantly asso-
ciated with advanced stages of disease (P=0.006 and P=0.05 for
p53 mutations and p53 protein overexpression respectively), and
they were more prevalent among poorly differentiated tumours
(P=0.01). In previous studies, no correlation between p53 alter-
ations and stage was reported (Marks et al, 1991; Hartmann et al,
1994; Kappes et al, 1995). Many variables may account for this
difference, including the method used in the study, the quality of
neoplastic samples (fixed or frozen) and the origin of material
(primary tumour or recurrence). It is interesting to note that in the
series of Marks et al (1991), only 15 out of 107 cancers analysed
were early stage, and in six ofthese cases tissue was obtained at the
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time of recurrence. On the other hand, Kappes et al (1995) exam-
ined different types of ovarian malignant tumours, including
epithelial and non-epithelial forms, primary and secondary
(metastatic) neoplasms. The authors reported that the presence
of p53 aberrations was not associated with stage of disease.
However, they observed a clear correlation between the frequency
ofp53 mutations and malignant potential of the tumours; somatic
mutations were very frequent in tumours of high grade and with
peritoneal spread. Concerning the relationship between p53 abnor-
malities and tumour differentiation, most authors (Bosari et al,
1993; Milner et al, 1993) have found that the presence ofp53 aber-
rations is significantly related to higher tumour grade. In agree-
ment with recently published data (Bosari et al, 1993; Levesque et
al, 1995), we have also observed that patients with p53 mutations
have a significantly shorter progression-free survival than patients
with p53-negative tumours (P=0.05). In addition, the observation
that benign and borderline tumours, as well as most of the early-
stage carcinomas, were negative for p53 abnormalities while
advanced-stage ovarian carcinomas frequently showed p53 alter-
ations strongly suggests that abnormalities in thep53 gene may be
associated with acquisition ofaggressive behaviour and metastatic
phenotype. In regard to this, Kupryjanczyk et al (1993) reported a
statistically significant association between p53 protein accumula-
tion in stage III disease and small primary tumour size at diagnosis,
suggesting that p53 abnormal proteins could accelerate the
metastatic spread.
In our panel of 33 patients with known response to chemo-
therapy, we found p53 mutations in 73% (19 out of 26) and p53
protein overexpression in 69% (18 out of 26) of the cases with
partial or absent response to chemotherapy. On the other hand, only
14% of the patients with complete response to chemotherapy
showed p53 aberrations. A very strong correlation (P=0.001)
emergedby cumulating the results ofthe genetic and immunohisto-
chemical analyses. These results can be explained by considering
the role of p53 in mediating the apoptotic process induced by
antiblastic drugs. Recent studies in Chinese hamster ovary cells
(Barry et al, 1990; Eastman, 1990) and in a preleukaemia cell line
(Miyashita and Reed, 1993) have demonstrated that the cytotoxic
effect of CDDP, one of the more effective and more commonly
used drugs in the treatment of ovarian cancer (Gately and Howell,
1993), is based on induction of apoptosis. The role of apoptosis in
cell killing by CDDP is also demonstrated by flow cytometric
methods (Ormerod et al, 1994). A link between the wild-type p53
gene and execution of apoptosis following DNA damage by anti-
cancer drugs (Lowe et al, 1993a) or ionizing radiation (Lowe et al,
1993b) has also been observed in different cell lines (O Connor et
al, 1993; Nabeya et al, 1995) and in murine model systems (Lowe
et al, 1994) with defective p53. In addition, by usingp53-null mice,
it has been shown that p53 inactivation causes a decrease in the
level of apoptosis and rapid tumour growth (Symmonds et al,
1994). Recently, it has been reported in mouse p53-expressing
tumours that acquired mutations in thep53 gene are associated with
both treatment resistance and relapse (Lowe et al, 1994). To the
best of our knowledge, the present study is the first to demonstrate
in vivo an association between p53 gene alterations and chemo-
sensitivity in human ovarian cancer. Similar results have recently
been obtained using an in vitro assay in a series of patients with
primary untreated breast carcinomas (Koechli et al, 1994).
When our manuscript was ready to be submitted, another study
(Righetti et al, 1996) presented experimental data very similar to
the results reported in the present study. The authors analysed 32
untreated patients with ovarian carcinoma, and they found a corre-
lation between p53 alterations and response to cisplatin-based
chemotherapy.
In conclusion, taken together our data strongly suggest that
in epithelial ovarian malignancies tumours showing p53 aberra-
tions are significantly less sensitive to chemotherapy and more
aggressive than those with functional p53. Thus, a routine analysis
of this gene could have profound implications for the treatment of
ovarian cancer.
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